Silo Pharma (SILO) $2.25, Now Our Favorite Psychedelic.
We Liked it at $3.50, we Love it at $2.25.
Down but not out. Now trading below the...
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Video: New Topical Drug Delivery System, NeuroDirect™
Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs.
https://youtu.be/2CGT7P9QEvo
Can...
Silo Pharma (SILO) Trades up 90% Friday, With 23 Million Shares Traded!
And We Weren't Watching!
It was Friday after all, and the last day of the year, and we were...
Doubling Down After ATAI’s (ATAI) Anti Depression Treatment Bombs in Front of FDA.
Both a bad day and a Good day for Psychedelics. The Psychedelic Sector Holds Firm.
Atai was founded in...
The Ketamine Endgame. Silo Pharmaceutical (SILO).
James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...
Latest article
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
